

Yanmei Liu, M.S.

SENIOR SCIENTIST II

CONTACT INFORMATION

BlueRidge Life Sciences
Pharmaceutical Commercialization
75 State Street
Suite 100 — #5783, #5784
Boston, MA 02109
Phone (781) 369-9754 (office)
Phone (508) 982-5111 (mobile)
yliu@heorstrategies.com

PROFESSIONAL PROFILE

Ms. Yanmei Liu is a Senior Scientist II with over 15 years' experience as a research scientist and statistical programmer working in Health Economics Outcomes Research (HEOR) and Real-World Evidence (RWE). She is skilled in managing large data sets, including administrative health care data, and is knowledgeable in analyzing and summarizing data in complex formats for a variety of different types of projects. Ms. Liu's skill set includes familiarity with ICD-10 diagnostic and procedure codes, and she has worked with IQVIA, Truven MarketScan, EMR/EHR, Optum, Medicare LDS, SEER cancer registry data, and survey data such as MEPS, HCUP, MCBS, and NHANES. She is proficient in the statistical programs SAS, SQL, Stata, and R.

EDUCATION AND DEGREES EARNED

M.S., Statistics, West Virginia University, Morgantown, WV
B.A., Economics, Hunan University, Hunan, China

PROFESSIONAL HONORS/AWARDS

Former employer, Brand Recognition Award for solving a client's challenge with a critical drug safety issue
Former employer, Above and Beyond Award for assisting in securing a multi-year client contract

SELECTED PROFESSIONAL EXPERIENCE

As a senior research scientist, provided data for proposals, protocols, final technical reports, and abstract writing. Loaded, validated, and managed data from a variety of sources. Derived, transformed, and summarized data based on analytical specifications, and documented derived data in analytic dataset creation. Used health care claims data to assist teams working on rare diseases. Mentored a junior programmer and provided technical review and oversight in data manipulation, analysis, and reporting.

As a statistical and analytic programmer, provided analytical datasets and results for multiple projects. Assisted research team in publishing articles on time and within budget. Helped students and study staff create analytic datasets and reports. Led custom analytic studies from definition of diseases and drug utilization, creation of appropriate outcome measures, creation of summary analytic files, to production of tables and graphs. Supported business development sales by providing disease and drug group population sample sizes.

As a consulting statistical analyst, completed an assignment with US Food and Drug Administration's Center for Food Safety and Applied Nutrition (FDA-CFSAN). Updated, analyzed, and reported on transaction and survey data for food safety standards. Created, maintained, and modified SAS programs on food safety data. Generated monthly and annual reports updating various food safety monitoring data with SAS programs

PUBLICATIONS

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, **Liu Y**, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. *Expert Rev Pharmacoecon Outcomes Res* 23(2):225–230; doi: 10.1080/14737167.2023.2160705.

Niu X, Dennen S, Dembek C, Laubmeier K, **Liu Y**, Veeranki S, Toco M, Williams GR. 2021. Hospitalization risk for adults with bipolar I disorder treated with oral atypical antipsychotics as adjunctive therapy with mood stabilizers: A retrospective analysis of Medicaid claims data. *Curr Ther Res* 94(Mar 27):100629; doi: 10.1016/j.curtheres.2021.100629.

Niu X, Veeranki S, Dennen S, Dembek C, Laubmeier K, **Liu Y**, Williams GR, Loebel A. 2021. Hospitalization risk among adults with bipolar I disorder treated with lurasidone versus other oral atypical antipsychotics: A retrospective analysis of Medicaid claims data. *Curr Med Res Opin* 37(5):839-846; doi: 10.1080/03007995.2021.1897557.

Niu X, Veeranki S, Dennen S, **Liu Y**, Shafrin J, Dembek C, et al. 2021. Hospitalization risk among adults with bipolar I disorder treated with oral atypical antipsychotics: A long-term data analysis of Medicaid claims data. *CNS Spectrums* 26(2):172-173 [abstract]; doi: 10.1017/S1092852920002813.

Sacks NC, Cyr PL, Louie AC, **Liu Y**, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. *Clin Ther* 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Sacks NC, Sharma A, Cyr PL, **Liu Y**, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. *Value in Health* 19(7):A611 [abstract].

Sacks NC, Cyr P, **Liu Y**, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. *Blood* 128(22):4780 [abstract]; doi: 10.1182/blood.V128.22.4780.4780.

PRESENTATIONS

Panattoni L, Hernandez J, **Liu Y**, Sacks NC, Higham R, Stephenson B, Armstrong A. Initial treatment patterns for newly diagnosed, commercially insured patients with psoriasis. Poster presentation, ISPOR, April 2021.

Sacks NC, **Liu Y**, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J, Rajagopalan H, Cyr PL, Jena AB. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. Poster presentation, American Heart Association Scientific Sessions, Anaheim, CA, November 2017.